- Home
- GMED vs JAZZ Comparison
GMED vs JAZZ Comparison
Compare GMED & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMED
- JAZZ
- Stock Information
- Founded
- GMED 2003
- JAZZ 2003
- Country
- GMED United States
- JAZZ Ireland
- Employees
- GMED N/A
- JAZZ N/A
- Industry
- GMED Medical/Dental Instruments
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- GMED Health Care
- JAZZ Health Care
- Exchange
- GMED Nasdaq
- JAZZ Nasdaq
- Market Cap
- GMED N/A
- JAZZ 6.1B
- IPO Year
- GMED 2012
- JAZZ 2007
- Fundamental
- Price
- GMED $71.01
- JAZZ $102.78
- Analyst Decision
- GMED Buy
- JAZZ Strong Buy
- Analyst Count
- GMED 13
- JAZZ 13
- Target Price
- GMED $96.91
- JAZZ $187.15
- AVG Volume (30 Days)
- GMED 1.3M
- JAZZ 1.6M
- Earning Date
- GMED 05-06-2025
- JAZZ 04-30-2025
- Dividend Yield
- GMED N/A
- JAZZ N/A
- EPS Growth
- GMED N/A
- JAZZ 41.75
- EPS
- GMED 0.75
- JAZZ 8.65
- Revenue
- GMED $2,519,355,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- GMED $8.52
- JAZZ $7.60
- Revenue Next Year
- GMED $6.73
- JAZZ $3.43
- P/E Ratio
- GMED $96.47
- JAZZ $11.80
- Revenue Growth
- GMED 60.62
- JAZZ 6.12
- 52 Week Low
- GMED $49.33
- JAZZ $95.49
- 52 Week High
- GMED $94.93
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- GMED 43.99
- JAZZ 31.87
- Support Level
- GMED $70.34
- JAZZ $100.42
- Resistance Level
- GMED $74.34
- JAZZ $104.12
- Average True Range (ATR)
- GMED 3.39
- JAZZ 6.41
- MACD
- GMED 0.25
- JAZZ -1.27
- Stochastic Oscillator
- GMED 53.31
- JAZZ 22.51
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.